Portal de Periódicos da CAPES

TESTOSTERONE REPLACEMENT THERAPY AFTER PRIMARY TREATMENT FOR PROSTATE CANCER

2005; Lippincott Williams & Wilkins; Volume: 173; Issue: 2 Linguagem: Inglês

10.1097/01.ju.0000143942.55896.64

1527-3792

Piyush K. Agarwal, Michael G. Oefelein,

Pharmacology and Obesity Treatment

No AccessJournal of UrologyAdult Urology: Sexual Function/Infertility1 Feb 2005TESTOSTERONE REPLACEMENT THERAPY AFTER PRIMARY TREATMENT FOR PROSTATE CANCER PIYUSH K. AGARWAL and MICHAEL G. OEFELEIN PIYUSH K. AGARWALPIYUSH K. AGARWAL and MICHAEL G. OEFELEINMICHAEL G. OEFELEIN View All Author Informationhttps://doi.org/10.1097/01.ju.0000143942.55896.64AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: A history of prostate cancer has been an absolute contraindication for testosterone supplementation. We studied a cohort of hypogonadal patients treated with radical retropubic prostatectomy (RRP) for organ confined prostate cancer to determine if testosterone replacement therapy (TRT) could be efficacious and administered safely without causing recurrent prostate tumor. Materials and Methods: Ten hypogonadal patients previously treated with RRP for organ confined prostate cancer were identified. They presented with low serum total testosterone (TT) and symptoms of hypogonadism after RRP. Patients had baseline serum determinations of prostate specific antigen (PSA) and TT, and were started on testosterone supplementation. They were assessed periodically for changes in PSA and TT, and for symptomatic improvement using the hormone domain of the Extended Prostate Inventory Composite Health Related Quality of Life questionnaire. Results: At a median followup of 19 months no patient had detectable (greater than 0.1 ng/ml) PSA. TT increased significantly after starting TRT from a mean ± SD of 197 ± 67 to 591 ± 180 ng/dl (p = 0.0002). The Hormone Domain of the Extended Prostate Inventory Composite Health Related Quality of Life questionnaire increased significantly from 38 ± 5 to 49 ± 3 (p = 0.00005), primarily due to a decrease in hot flashes and an increase in energy level. Conclusions: At a median of 19 months of TRT hypogonadal patients with a history of prostate cancer had no PSA recurrence and had statistically significant improvements in TT and hypogonadal symptoms. In highly select patients after RRP TRT can be administered carefully and with benefit to hypogonadal patients with prostate cancer. References 1 Morales, A., Carson, C., Hellstrom, W., Lipshultz, L. and Morgentaler, A.: 2/11/2003 Position statement on Diagnosis, Treatment, and Monitoring of Male Late Onset Hypogonadism by Sexual Medicine Society of North America, Inc., A Specialty Society of the AUA. Available at http://www.smsna.org/about/dtmmloh.asp. Accessed July 2, 2004 Google Scholar 2 : Baltimore Longitudinal Study of Aging: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab2001; 86: 724. Google Scholar 3 : Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab2000; 85: 2670. Google Scholar 4 : Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab1997; 82: 1661. Google Scholar 5 : Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry2003; 160: 105. Google Scholar 6 : Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl2001; 22: 718. Google Scholar 7 : Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl2003; 24: 299. Google Scholar 8 : Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl2002; 23: 922. Google Scholar 9 : Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol2003; 170: 2348. Link, Google Scholar 10 : Avoid testosterone in prostate cancer patients, experts advise. Urol Times2003; 31: 34. Google Scholar 11 : The effects of castration on advanced carcinoma of the prostate gland. Arch Surg1941; 43: 209. Google Scholar 12 : Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology2000; 56: 899. Crossref, Medline, Google Scholar 13 : Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med2004; 350: 482. Google Scholar 14 : Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology1999; 53: 423. Google Scholar 15 : Prostate cancer after exogenous testosterone treatment for impotence. J Urol1997; 157: 1845. Link, Google Scholar 16 : Epidemiology, etiology and prevention of prostate cancer. In: . Philadelphia: W. B. Saunders Co.2002: 3011. sect. XI, chapt. 85. Google Scholar 17 : Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice. J Urol1991; 145: 631. Link, Google Scholar 18 : The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol1981; 126: 373. Google Scholar 19 : Occult prostate cancer in men with low serum testosterone levels. JAMA1996; 276: 1904. Crossref, Medline, Google Scholar 20 : Is low serum free testosterone a marker for high grade prostate cancer?. J Urol2000; 163: 824. Link, Google Scholar 21 : Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol2003; 169: 1670. Link, Google Scholar 22 : Influence of radical prostatectomy on serum hormone levels. J Urol1998; 160: 449. Link, Google Scholar 23 : Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology2002; 60: 869. Google Scholar From the Department of Urology, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio© 2005 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byOry J, Flannigan R, Lundeen C, Huang J, Pommerville P and Goldenberg S (2016) Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic OutcomesJournal of Urology, VOL. 196, NO. 4, (1082-1089), Online publication date: 1-Oct-2016.Pastuszak A, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners W, Sarosdy M, Yang C, Carrion R, Lipshultz L and Khera M (2015) Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate CancerJournal of Urology, VOL. 194, NO. 5, (1271-1276), Online publication date: 1-Nov-2015.Pastuszak A, Pearlman A, Lai W, Godoy G, Sathyamoorthy K, Liu J, Miles B, Lipshultz L and Khera M (2013) Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical ProstatectomyJournal of Urology, VOL. 190, NO. 2, (639-644), Online publication date: 1-Aug-2013.Morgentaler A (2018) Testosterone Therapy in Men With Prostate Cancer: Scientific and Ethical ConsiderationsJournal of Urology, VOL. 189, NO. 1S, (S26-S33), Online publication date: 1-Jan-2013.Morgentaler A, Lipshultz L, Bennett R, Sweeney M, Avila D and Khera M (2011) Testosterone Therapy in Men With Untreated Prostate CancerJournal of Urology, VOL. 185, NO. 4, (1256-1261), Online publication date: 1-Apr-2011.Morgentaler A (2009) Testosterone Therapy in Men With Prostate Cancer: Scientific and Ethical ConsiderationsJournal of Urology, VOL. 181, NO. 3, (972-979), Online publication date: 1-Mar-2009. Volume 173Issue 2February 2005Page: 533-536 Advertisement Copyright & Permissions© 2005 by American Urological Association, Inc.Keywordsprostateprostatectomyprostate-specific antigenhypogonadismprostatic neoplasmsMetricsAuthor Information PIYUSH K. AGARWAL More articles by this author MICHAEL G. OEFELEIN Financial interest and/or other relationship with Novartis, Sanofi, Ferring and Atrix Laboratories. More articles by this author Expand All Advertisement PDF downloadLoading ...